Celebrex

Property	Information
Drug Name	Celebrex (Celecoxib) and Other NSAIDs
FDA Approval	Yes (Celebrex is FDA-approved for arthritis and pain, but not specifically for cancer treatment)
Used for	Investigational use in cancer treatment due to anti-inflammatory, anti-angiogenic, and potential tumor growth inhibition properties
Clinical Trial Phase	Early clinical trials and observational studies, including phase 2 trials combining Celebrex with conventional cancer treatments
Clinical Trial Explanation	Not specified
Common Side Effects	Generally well-tolerated; potential gastrointestinal issues with long-term use of some NSAIDs. Celebrex designed to minimize COX-1 inhibition and related stomach issues.
OS without	Not specified
OS with	Not specifically documented; clinical trials have shown mixed results, with some indicating significant benefit when added to standard chemotherapy protocols
PFS without	Not specified
PFS with	Variable across studies; for example, a study combining Temodar with Celebrex showed a PFS-6 of 35%, another combining Celebrex with CPT-11 showed PFS-6 of 25%
Usefulness Rating	3
Usefulness Explanation	Not specified
Toxicity Level	Not specified
Toxicity Explanation	Not specified

Notes: The use of Celebrex and other NSAIDs in cancer treatment is based on their anti-inflammatory properties, inhibition of COX-2 enzymes, and subsequent reduction in angiogenesis and tumor growth. While preclinical and early clinical research indicates potential benefits, including immune system enhancement and apoptosis induction, results from clinical trials have been mixed. The mechanisms underlying NSAIDs' anti-cancer effects, particularly in gliomas, suggest a promising avenue for research, emphasizing the need for further large-scale, randomized clinical trials to better understand their efficacy and optimal integration into cancer therapy regimens.

From Ben Williams Book: Not specified

Loading comments...